关键词: 凝血酶-抗凝血酶复合物, 纤维蛋白溶解, 凝血酶激活的纤溶抑制物, 胃癌

Abstract:

 Objective   To explore the correlation between different stages of gastric cancer and the levels  of thrombin-activated fibrinolysis inhibitor (TAFI) and thrombin-antithrombin (TAT).  Methods  Blood samples were collected from 48 patients with gastric cancer (gastric cancer group), 34 patients with benign gastric disorders (benign gastric disorder group), and 50 healthy individuals (healthy control group). Plasma levels of TAFI, TAT, D-D and fibrinogen were measured using a chromogenic substrate method and ELISA. Then their correlations with different stages of gastric cancer were analyzed. The power of test and the best diagnostic value of TAFI and TAT were evaluated with receiver operating characteristic curve (ROC curve).  Results  Compared with healthy control group and benign gastric disorder group, the gastric cancer group had higher TAFI, D-D, fibrinogen, and TAT levels (P<0.05). When TAFI level was 28.85μg/mL, the sensitivity and specificity was 0.646 and 0.869, respectively. When TAT level was 31.50ng/mL, the sensitivity and specificity was 0.813 and 0.786, respectively. Conclusion  Patients with gastric cancer have significantly higher TAFI and TAT levels. TAFI and TAT are indicators of thrombosis tendency, which can be used to evaluate the risk of gastric cancer.

Key words: Thrombin-activated fibrinolysis inhibitor, Fibrinolysis, Gastric cancer, Thrombin-antithrombin complex